688336 三生国健
已收盘 10-26 15:00:00
资讯
新帖
简况
股市必读：三生国健三季报 - 第三季度单季净利润同比增长3.65%
证券之星 · 10-26 01:54
股市必读：三生国健三季报 - 第三季度单季净利润同比增长3.65%
国金证券：给予三生国健买入评级
证券之星 · 10-23
国金证券：给予三生国健买入评级
三生国健前三季度净利润增长47.29% 自免管线价值逐步兑现
东方财富网 · 10-23
三生国健前三季度净利润增长47.29% 自免管线价值逐步兑现
三生国健（688336）披露2026年第三季度报告，10月22日股价下跌5.47%
证券之星 · 10-22
三生国健（688336）披露2026年第三季度报告，10月22日股价下跌5.47%
三生国健最新公告：前三季度净利润同比增长47.29%
证券之星 · 10-22
三生国健最新公告：前三季度净利润同比增长47.29%
10月22日三生国健跌5.47%，平安医疗健康混合A基金重仓该股
证券之星 · 10-22
10月22日三生国健跌5.47%，平安医疗健康混合A基金重仓该股
三生国健（688336）10月21日主力资金净卖出2070.07万元
证券之星 · 10-22
三生国健（688336）10月21日主力资金净卖出2070.07万元
三生国健（688336）10月13日主力资金净卖出1520.59万元
证券之星 · 10-14
三生国健（688336）10月13日主力资金净卖出1520.59万元
10月8日三生国健跌8.52%，平安医疗健康混合A基金重仓该股
证券之星 · 10-08
10月8日三生国健跌8.52%，平安医疗健康混合A基金重仓该股
三生国健（688336）9月29日主力资金净买入2184.48万元
证券之星 · 09-30
三生国健（688336）9月29日主力资金净买入2184.48万元
9月24日三生国健跌5.20%，平安医疗健康混合A基金重仓该股
证券之星 · 09-24
9月24日三生国健跌5.20%，平安医疗健康混合A基金重仓该股
三生“少帅”娄竞：从科学家到操盘手，是药二代更是创一代
蓝鲸财经 · 09-23
三生“少帅”娄竞：从科学家到操盘手，是药二代更是创一代
翰森制药TYK2新药III期告捷，直面进口、国产、生物制剂三面挤压：商业化突围挑战重重，第二增长曲线仍待验证
同花顺 · 09-23
翰森制药TYK2新药III期告捷，直面进口、国产、生物制剂三面挤压：商业化突围挑战重重，第二增长曲线仍待验证
9月14日三生国健涨5.04%，平安医疗健康混合A基金重仓该股
证券之星 · 09-14
9月14日三生国健涨5.04%，平安医疗健康混合A基金重仓该股
三生国健涨5.04%，中邮证券一周前给出“买入”评级
证券之星 · 09-14
三生国健涨5.04%，中邮证券一周前给出“买入”评级
每周股票复盘：三生国健（688336）审议中期利润分配方案
证券之星 · 09-13
每周股票复盘：三生国健（688336）审议中期利润分配方案
三生国健（688336）披露2026年中期利润分配方案，8月31日股价上涨0.07%
证券之星 · 08-31
三生国健（688336）披露2026年中期利润分配方案，8月31日股价上涨0.07%
每周股票复盘：三生国健（688336）TSLP/IL-4双抗吸入剂优势显著
证券之星 · 08-30
每周股票复盘：三生国健（688336）TSLP/IL-4双抗吸入剂优势显著
三生国健：8月21日召开业绩说明会，东北证券、华西证券等多家机构参与
证券之星 · 08-27
三生国健：8月21日召开业绩说明会，东北证券、华西证券等多家机构参与
三生国健2026半年报归母净利猛增95%！“剪刀差”彰显多维布局成效，自免龙头开启密集收获期
蓝鲸财经 · 08-25
三生国健2026半年报归母净利猛增95%！“剪刀差”彰显多维布局成效，自免龙头开启密集收获期
加载更多
公司概况
公司名称：
三生国健药业(上海)股份有限公司
所属行业：
医药制造业
上市日期：
2020-07-22
主营业务：
三生国健药业(上海)股份有限公司的主营业务是抗体药物的研发、生产和销售。公司的主要产品是益赛普（重组人II型肿瘤坏死因子受体-抗体融合蛋白）。
发行价格：
28.18
{"stockData":{"symbol":"688336","market":"SH","secType":"STK","nameCN":"三生国健","latestPrice":33.91,"timestamp":1792998000000,"preClose":33.76,"halted":0,"volume":3679723,"delay":0,"changeRate":0.0044,"floatShares":896000000,"shares":896000000,"eps":3.4455,"marketStatus":"已收盘","change":0.15,"latestTime":"10-26 15:00:00","open":33.57,"high":34.38,"low":33.48,"amount":125000000,"amplitude":0.0267,"askPrice":33.91,"askSize":3,"bidPrice":33.88,"bidSize":24,"shortable":0,"etf":0,"ttmEps":3.4455,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793064600000},"marketStatusCode":5,"adr":0,"adjPreClose":33.76,"symbolType":"stock_kcb","openAndCloseTimeList":[[1792978200000,1792985400000],[1792990800000,1792998000000]],"highLimit":37.14,"lowLimit":30.38,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":896225429,"isCdr":false,"pbRate":3.5,"roa":"--","peRate":9.841823,"roe":"6.84%","epsLYR":4.7,"committee":0.139706,"marketValue":30391000000,"turnoverRate":0.0041,"status":0,"afterMarket":{"amount":8579.23,"volume":253,"close":33.91,"buyVolume":4147,"sellVolume":0,"time":1793000037746,"indexStatus":"已收盘 10-26 15:30:00","preClose":33.76},"floatMarketCap":30391000000},"requestUrl":"/m/hq/s/688336","defaultTab":"news","newsList":[{"id":"2678353136","title":"股市必读：三生国健三季报 - 第三季度单季净利润同比增长3.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678353136","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678353136?lang=zh_cn&edition=full","pubTime":"2026-10-26 01:54","pubTimestamp":1792950853,"startTime":"0","endTime":"0","summary":"截至2026年10月23日收盘，三生国健报收于33.76元，上涨3.88%，换手率0.67%，成交量6.02万手，成交额1.96亿元。第三季度单季度主营收入5.27亿元，同比上升11.14%；归母净利润2.16亿元，同比上升3.65%；扣非净利润1.83亿元，同比下降6.38%；负债率4.43%，毛利率81.19%，投资收益4949.23万元，财务费用4533.48万元。公司公告汇总三生国健：2026年第三季度报告2026年第三季度营业收入52,677.72万元，同比增长11.14%；年初至报告期末营业收入139,248.04万元，同比增长24.77%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600000556.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677289926","title":"国金证券：给予三生国健买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2677289926","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677289926?lang=zh_cn&edition=full","pubTime":"2026-10-23 19:00","pubTimestamp":1792753212,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司甘坛焕,唐玉青近期对三生国健进行研究并发布了研究报告《授权收入持续驱动业绩高增，在研管线密集推进》，给予三生国健买入评级。 风险提示 研发及商业化不及预期风险、大股东持股集中及关联交易风险最新盈利预测明细如下：该股最近90天内共有8家机构给出评级，买入评级5家，增持评级3家；过去90天内机构目标均价为55.82。本文数据来源于国金证券股份有限公司，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300037398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677192634","title":"三生国健前三季度净利润增长47.29% 自免管线价值逐步兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2677192634","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677192634?lang=zh_cn&edition=full","pubTime":"2026-10-23 18:06","pubTimestamp":1792749960,"startTime":"0","endTime":"0","summary":"上证报中国证券网讯（记者常华科）10月22日晚间，三生国健披露2026年三季报。公告显示，公司前三季度营业收入13.92亿元，同比增长24.77%；归母净利润5.87亿元，同比增长47.29%；扣非归母净利润4.42亿元，同比增长25.55%。与此同时，公司持续加码创新研发投入，前三季度研发费用同比增长35.68%。“公司将保持每年至少一款新品或新适应症申报或上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://stock.eastmoney.com/news/11134,202610233906407687.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/news/11134,202610233906407687.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677937961","title":"三生国健（688336）披露2026年第三季度报告，10月22日股价下跌5.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677937961","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677937961?lang=zh_cn&edition=full","pubTime":"2026-10-22 22:20","pubTimestamp":1792678827,"startTime":"0","endTime":"0","summary":"截至2026年10月22日收盘，三生国健报收于32.5元，较前一交易日下跌5.47%，最新总市值为291.27亿元。该股当日开盘34.35元，最高34.49元，最低32.26元，成交额达1.76亿元，换手率为0.59%。近日，三生国健药业（上海）股份有限公司披露《2026年第三季度报告》。报告显示，本报告期营业收入52,677.72万元，同比增长11.14%；年初至报告期末营业收入139,248.04万元，同比增长24.77%。利润总额年初至报告期末为62,186.85万元，同比增长50.39%；归属于上市公司股东的净利润为58,746.39万元，同比增长47.29%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200042770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677959653","title":"三生国健最新公告：前三季度净利润同比增长47.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677959653","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677959653?lang=zh_cn&edition=full","pubTime":"2026-10-22 18:02","pubTimestamp":1792663379,"startTime":"0","endTime":"0","summary":"三生国健(688336.SH)公告称，第三季度营业收入为5.27亿元，同比增长11.14%；归属于上市公司股东的净利润为2.16亿元，同比增长3.65%。前三季度营业收入为13.92亿元，同比增长24.77%；归属于上市公司股东的净利润为5.87亿元，同比增长47.29%。注：公司Q3净利润2.16亿，Q2净利润1.93亿，据此计算，Q3净利润环比增长11%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200031416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677348958","title":"10月22日三生国健跌5.47%，平安医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2677348958","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677348958?lang=zh_cn&edition=full","pubTime":"2026-10-22 16:37","pubTimestamp":1792658276,"startTime":"0","endTime":"0","summary":"证券之星消息，10月22日三生国健跌5.47%创60日新低，收盘报32.5元，换手率0.59%，成交量5.3万手，成交额1.76亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共33家，其中持有数量最多的公募基金为平安基金的平安医疗健康混合A。平安医疗健康混合A目前规模为17.61亿元，最新净值2.1586，较上一交易日上涨0.4%，近一年下跌15.97%。平安医疗健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200028545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239","159760"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677898988","title":"三生国健（688336）10月21日主力资金净卖出2070.07万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677898988","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677898988?lang=zh_cn&edition=full","pubTime":"2026-10-22 08:34","pubTimestamp":1792629285,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月21日收盘，三生国健报收于34.38元，下跌2.05%，换手率0.45%，成交量4.0万手，成交额1.4亿元。近5日资金流向一览见下表：三生国健融资融券信息显示，融资方面，当日融资买入1565.96万元，融资偿还2071.11万元，融资净偿还505.15万元。三生国健主营业务：从事抗体药物的研发、生产及销售业务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200007099.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675957783","title":"三生国健（688336）10月13日主力资金净卖出1520.59万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675957783","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675957783?lang=zh_cn&edition=full","pubTime":"2026-10-14 08:25","pubTimestamp":1791937536,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月13日收盘，三生国健报收于36.46元，下跌3.54%，换手率0.58%，成交量5.23万手，成交额1.9亿元。近5日资金流向一览见下表：三生国健融资融券信息显示，融资方面，当日融资买入2315.04万元，融资偿还2529.65万元，融资净偿还214.61万元。三生国健主营业务：从事抗体药物的研发、生产及销售业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400007165.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673275370","title":"10月8日三生国健跌8.52%，平安医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2673275370","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673275370?lang=zh_cn&edition=full","pubTime":"2026-10-08 16:39","pubTimestamp":1791448772,"startTime":"0","endTime":"0","summary":"证券之星消息，10月8日三生国健跌8.52%，收盘报37.9元，换手率0.99%，成交量8.89万手，成交额3.46亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共33家，其中持有数量最多的公募基金为平安基金的平安医疗健康混合A。平安医疗健康混合A目前规模为17.61亿元，最新净值2.3908，较上一交易日上涨3.23%，近一年下跌14.57%。平安医疗健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800021310.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159760","688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671259862","title":"三生国健（688336）9月29日主力资金净买入2184.48万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671259862","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671259862?lang=zh_cn&edition=full","pubTime":"2026-09-30 08:19","pubTimestamp":1790727556,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月29日收盘，三生国健报收于40.68元，上涨3.78%，换手率0.93%，成交量8.34万手，成交额3.35亿元。近5日资金流向一览见下表：三生国健融资融券信息显示，融资方面，当日融资买入2477.37万元，融资偿还2940.38万元，融资净偿还463.02万元。三生国健主营业务：从事抗体药物的研发、生产及销售业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000006503.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669463186","title":"9月24日三生国健跌5.20%，平安医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669463186","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669463186?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:38","pubTimestamp":1790239122,"startTime":"0","endTime":"0","summary":"证券之星消息，9月24日三生国健跌5.20%，收盘报39.21元，换手率0.79%，成交量7.05万手，成交额2.82亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共33家，其中持有数量最多的公募基金为平安基金的平安医疗健康混合A。平安医疗健康混合A目前规模为17.61亿元，最新净值2.3952，较上一交易日上涨0.78%，近一年下跌14.36%。平安医疗健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400028548.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159760","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669548376","title":"三生“少帅”娄竞：从科学家到操盘手，是药二代更是创一代","url":"https://stock-news.laohu8.com/highlight/detail?id=2669548376","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669548376?lang=zh_cn&edition=full","pubTime":"2026-09-23 20:02","pubTimestamp":1790164971,"startTime":"0","endTime":"0","summary":"三生官方资料将其列为益比奥、特比澳开发的领导科学家和主要研究员。2007年三生制药登陆纳斯达克，是国内较早赴美上市的生物药企之一。2015年三生回港上市，公司大事记称其当年成为全球生物制药领域受关注IPO之一。娄竞接手后先扩后收，早期保留赛普汀等肿瘤抗体，2020年前后逐步把资源收回到自身免疫。国健年报披露，相关款项三生国健占30%、沈阳三生占70%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1790134731525398876","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0239","01530","BK1161","HK0000165453.HKD","688336","BK1593","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669173759","title":"翰森制药TYK2新药III期告捷，直面进口、国产、生物制剂三面挤压：商业化突围挑战重重，第二增长曲线仍待验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2669173759","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669173759?lang=zh_cn&edition=full","pubTime":"2026-09-23 08:13","pubTimestamp":1790122380,"startTime":"0","endTime":"0","summary":"翰森制药（03692.HK）旗下口服TYK2抑制剂在III期临床中达到主要终点，标志着其在自身免疫疾病领域迎来重要里程碑。9月21日，翰森制药公告称，自研酪氨酸激酶2（TYK2）选择性变构抑制剂HS-10 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260923/c680191975.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260923/c680191975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688336","688382","BK0239","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667659299","title":"9月14日三生国健涨5.04%，平安医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667659299","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667659299?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:37","pubTimestamp":1789375044,"startTime":"0","endTime":"0","summary":"证券之星消息，9月14日三生国健涨5.04%，收盘报39.99元，换手率0.84%，成交量7.52万手，成交额2.98亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共33家，其中持有数量最多的公募基金为平安基金的平安医疗健康混合A。平安医疗健康混合A目前规模为17.61亿元，最新净值2.1873，较上一交易日下跌1.88%，近一年下跌23.4%。平安医疗健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400021134.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688336","159760"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667246659","title":"三生国健涨5.04%，中邮证券一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2667246659","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667246659?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:37","pubTimestamp":1789375036,"startTime":"0","endTime":"0","summary":"今日三生国健涨5.04%，收盘报39.99元。2026年9月4日，中邮证券研究员盛丽华,徐智敏发布了对三生国健的研报《授权收入驱动业绩高增，创新管线迈入密集兑现期》，该研报对三生国健给出“买入”评级。此外，国金证券研究员甘坛焕,唐玉青，开源证券研究员余汝意,聂媛媛近期也对该股发布了研报，同样给出“买入”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400021132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667507804","title":"每周股票复盘：三生国健（688336）审议中期利润分配方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2667507804","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667507804?lang=zh_cn&edition=full","pubTime":"2026-09-13 01:41","pubTimestamp":1789234869,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，三生国健报收于38.07元，较上周的42.16元下跌9.7%。本周，三生国健9月7日盘中最高价报42.38元。三生国健当前最新总市值341.19亿元，在生物制品板块市值排名3/51，在两市A股市值排名571/5218。出席股东所持表决权占公司总表决权的84.7955%。两项议案分别作为普通决议和特别决议获得通过，其中利润分配方案对中小投资者单独计票。国浩律师事务所对本次会议进行见证并出具法律意见书，确认会议召集、召开及表决程序合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663072863","title":"三生国健（688336）披露2026年中期利润分配方案，8月31日股价上涨0.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663072863","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663072863?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:31","pubTimestamp":1788172287,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，三生国健报收于42.6元，较前一交易日上涨0.07%，最新总市值为381.79亿元。该股当日开盘42.15元，最高42.78元，最低41.35元，成交额达2.1亿元，换手率为0.56%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100028632.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663010442","title":"每周股票复盘：三生国健（688336）TSLP/IL-4双抗吸入剂优势显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2663010442","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663010442?lang=zh_cn&edition=full","pubTime":"2026-08-30 03:40","pubTimestamp":1788032422,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，三生国健报收于42.57元，较上周的47.65元下跌10.66%。本周，三生国健8月24日盘中最高价报47.7元。三生国健当前最新总市值381.52亿元，在生物制品板块市值排名3/51，在两市A股市值排名533/5211。本周关注点来自机构调研要点：TSLP/IL-4R双抗通过协同抑制实现对II型和非II型炎症的全面控制。机构调研要点问：公司如何看待TSLP/IL?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000001164.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085857","title":"三生国健：8月21日召开业绩说明会，东北证券、华西证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085857","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662085857?lang=zh_cn&edition=full","pubTime":"2026-08-27 21:58","pubTimestamp":1787839096,"startTime":"0","endTime":"0","summary":"辉瑞将该品种列为自身肿瘤管线重点布局产品，现阶段已牵头推进9项I/II/III期全球多中心临床试验，覆盖非小细胞肺癌、结直肠癌等多个实体瘤适应症。三生国健主营业务：从事抗体药物的研发、生产及销售业务。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700054205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000686","688336","BK0183","002926","BK0188","BK0276","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662783663","title":"三生国健2026半年报归母净利猛增95%！“剪刀差”彰显多维布局成效，自免龙头开启密集收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2662783663","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662783663?lang=zh_cn&edition=full","pubTime":"2026-08-25 11:48","pubTimestamp":1787629718,"startTime":"0","endTime":"0","summary":"8月20日晚间，三生国健交出2026年半年度成绩单，归母净利润3.71亿元，同比猛增95.10%，盈利能力显著跑赢营收，展现出极强的业绩“含金量”。半年报显示，三生国健2026年上半年研发投入合计2.45亿元，同比增长32.41%，研发投入占营收比重达30.93%，公司持续布局双抗、三抗、吸入抗体等前沿方向。根据国金证券研报预测，该产品预计有望于2027年上半年获批上市。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787629517879306042","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793057186023,"stockEarnings":[{"period":"1week","weight":-0.0091},{"period":"1month","weight":-0.1352},{"period":"3month","weight":-0.1955},{"period":"6month","weight":-0.3226},{"period":"1year","weight":-0.0955},{"period":"ytd","weight":-0.1679}],"compareEarnings":[{"period":"1week","weight":-0.009},{"period":"1month","weight":-0.0491},{"period":"3month","weight":-0.0304},{"period":"6month","weight":-0.0998},{"period":"1year","weight":-0.064},{"period":"ytd","weight":-0.0684}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"三生国健药业(上海)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"21636人(较上一季度增加5.09%)","perCapita":"41422股","listingDate":"2020-07-22","address":"上海市浦东新区中国(上海)自由贸易试验区李冰路399号","registeredCapital":"89622万元","survey":" 三生国健药业(上海)股份有限公司的主营业务是抗体药物的研发、生产和销售。公司的主要产品是益赛普（重组人II型肿瘤坏死因子受体-抗体融合蛋白）。","listedPrice":28.18},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三生国健(688336)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三生国健(688336)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三生国健,688336,三生国健股票,三生国健股票老虎,三生国健股票老虎国际,三生国健行情,三生国健股票行情,三生国健股价,三生国健股市,三生国健股票价格,三生国健股票交易,三生国健股票购买,三生国健股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三生国健(688336)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三生国健(688336)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}